Publications, Pharmaceutical

Delivering On The Promises of Intranasal Vaccination

Intranasal vaccination offers a number of valuable benefits. Nasal vaccines are easy to self-administer, non-invasive and trigger a broad immune response, notably mucosal immunity. This article reviews the advantages of intranasal vaccination, the challenges associated with developing nasal spray vaccines and recent advances in the field. COVID-19 has had a hugely disruptive impact on the vaccines market. Although only four nasal spray vaccines are currently in commercial use a significant number of intranasal spray vaccines for COVID-19 are in development, holding out the promise of adding mucosal immunity to improve resistance to the virus. The design of the drug delivery technology and emerging strategies for successful vaccine formulation are discussed.

For more information on ONdrugDelivery.

Download Publication
Author(s): Dr. Julie Suman Nektaria Karavas
18 Nov 2021

This Might Also Be of Interest

21 Apr 2022

Aptar Pharma Q&A on trends and challenges in nasal drug delivery

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
4 Apr 2022

Why it is time to think differently about Nasal delivery of Biologics

Publications, Pharmaceutical, Innovation & Insights, Brand Differentiation, Market Insights, Product Solutions

Read More
25 Feb 2022

Aptar Pharma discusses intranasal administration for CNS therapeutics

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
15 Feb 2022

New solutions for pre-clinical discovery in respiratory healthcare

Webinars, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 11 12 13 14 15 25
Back To Top